Candel Therapeutics (CADL) Stifel 2026 Healthcare Conference 2026 summary

Prostate cancer immunology and clinical evidence

• SITC Phase IIa PrTK05 reproduced prior biodistribution and shedding findings using updated methods; the replication-defective construct was no longer detectable within a few months.

• After local prostate delivery, circulating cytotoxic and proliferating CD8+ T cells, effector-memory cells and central-memory cells increased, supporting systemic immune activation from localized treatment.

• Phase III primary endpoint of disease-free survival was achieved in Dec 2024; secondary evidence included PSA nadir below 0.2 ng/mL and more negative two-year biopsies versus placebo.

• Exploratory follow-up showed separation in biochemical failure, time to metastasis and time to salvage therapy; high-risk subgroup event counts were small, while 85% of trial patients had intermediate-risk disease.

• Benefit versus placebo was reported independent of EBRT type and short-term ADT use; the recently updated NCCN guidance for unfavorable intermediate-risk disease leaves ADT to shared decision-making.

Adoption and reimbursement outlook

• Physician research indicated strong interest in clinical use; urologists and radiation oncologists already coordinate care and perform prostate procedures, supporting integration into existing practice.

• Expected reimbursement would cover both the procedure and medicine; payer research cited a $285,000 median annual price range for GU tumors, equivalent in this case to three administrations, with further research and negotiation ongoing.

• Payers valued the achieved primary endpoint, supporting follow-up evidence, no increase in serious adverse events versus placebo and a finite treatment course; reduced future ADT costs were also highlighted.

Non-small cell lung cancer

• Phase II data in heavily pretreated patients with advanced NSCLC were published with immunological biomarker findings; 90% had failed checkpoint inhibitors, and over 50% had low or undetectable PD-L1.

• Agl महत्वपूर्ण? Two administrations delivered during bronchoscopy were described as generally well tolerated; Phase III protocol incorporates findings favoring non-squamous disease and thoracic lesions, and accounts for possible pseudoprogression at six weeks.